Fund HoldingsGILEAD SCIENCES, INC.

Total Portfolio Value
$1.65B
Total Bought
$11.75M
Total Sold
$771.68M
Net Transaction
-$759.94M
Filing Period:
Securities
SharesValue ($K)
Q1 2026
Q2 2026
Change
Q1 2026
Q2 2026
Weight (%)
Change
Arcus Biosciences Inc.(RCUS)31,424,76031,424,7600678,775968,82558.76%+290,051
Assembly Biosciences Inc.4,505,3914,977,089+471,698125,025136,7708.30%+11,746
Kyverna Therapeutics Inc.(KYTX)4,126,1194,126,119035,60836,7642.23%+1,155
Xilio Therapeutics Inc.(XLO)650,389650,38905,4706,2310.38%+761
Lakefront Biotherapeutics(LKFT)16,707,47716,707,4770501,224500,15830.34%-1,067
Arcellx Inc
COMMON STOCK
6,720,8030-6,720,803771,6830-771,683
Page 1 of 1
GILEAD SCIENCES, INC. — 13F Holdings — Q2 2026 | TickerTrail